Jun 4, 2021
The FDA approves once-weekly semaglutide for chronic weight management in eligible adults alongside diet and physical activity.
GLP-1 medicines bring peptide-based therapeutics into a much wider public conversation. A prescription approval does not validate unrelated peptides sold for wellness.